Unknown

Dataset Information

Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy.


ABSTRACT: Modulating effector immune cells via monoclonal antibodies (mAbs) and facilitating the co-engagement of T cells and tumor cells via chimeric antigen receptor- T cells or bispecific T cell-engaging antibodies are two typical cancer immunotherapy approaches. We speculated that immobilizing two types of mAbs against effector cells and tumor cells on a single nanoparticle could integrate the functions of these two approaches, as the engineered formulation (immunomodulating nano-adaptor, imNA) could potentially associate with both cells and bridge them together like an 'adaptor' while maintaining the immunomodulatory properties of the parental mAbs. However, existing mAbs-immobilization strategies mainly rely on a chemical reaction, a process that is rough and difficult to control. Here, we bui

SUBMITTER: Jiang CT 

PROVIDER: S-EPMC7921676 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature